SCIENCE & TECHNOLOGY
INTRODUCTION
Amarin's development compound, AMR101, is supported by a proprietary Lipophilic Platform which is described in more detail in this section. Also described is the closely related proprietary Targeted Lipid Transport Platform which offers Amarin a source of new development candidates, of which AMR103 for Parkinson's disease is the lead candidate.
